Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Phase 1 Trials In a first-in-human, randomized, placebo-controlled, single ascending dose, phase 1 trial in healthy participants, retatrutide demonstrated a favourable safety profile (similar to other incretin-based therapies) and early signs of efficacy with dose-dependent WL [42]
GLP-1 agonists are not a replacement for antihypertensive therapy but may complement it
Responsible AI
Computational investigation of cholesterol binding sites on mitochondrial VDAC
US$ 28.15
US$ 21.07
US$ 29.22
US$ 24.99
